Biogen withdraws ‘divisional’ patent after EU antitrust questions
Biogen gave up its pursuit of extra patent protection for its multiple sclerosis drug earlier this month after it received questions from EU investigators over a possible antitrust abuse. The US...To view the full article, register now.
Already a subscriber? Click here to view full article